DSIP

What it is

Delta sleep-inducing peptide is a nonapeptide first described in the 1970s in sleep research. The name reflects early experiments suggesting that a peptide isolated from cerebral venous blood during sleep could affect delta-wave sleep in mammals. MeSH describes DSIP as a nonapeptide found in neurons, peripheral organs, and plasma and notes reported effects beyond sleep, including electrophysiologic activity, neurotransmitter levels, circadian and locomotor patterns, hormonal levels, psychological performance, and interactions with neuropharmacologic drug withdrawal^{[9 ]}.

Chemical structure

DSIP is a nine-amino-acid peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and molecular formula C35H48N10O15^{[1 ]}. PubChem and MeSH identify it as emideltide or delta sleep-inducing peptide, a nonapeptide associated historically with delta sleep and other neuroendocrine effects^{[1 ,9 ]}.

Mechanism unsettled

The name can overstate what is known. “Delta sleep-inducing” suggests a reliable sleep drug, but the human clinical evidence is old, small, and inconsistent^{[10 –11 ]}. Modern sleep-medicine guidelines and FDA-approved insomnia treatments do not include DSIP as an approved therapy.

DSIP’s mechanism is not settled. The peptide has been discussed in relation to sleep architecture, stress hormones, opioid systems, and other neuroendocrine effects, but no FDA-approved label or validated clinical mechanism exists. Because the peptide is rapidly degraded and has no approved formulation, public claims about injected, intranasal, or sublingual DSIP should not be treated as established.

When marketed online, DSIP is usually sold as a research peptide for sleep quality, deep sleep, stress resilience, withdrawal support, or recovery. No FDA-approved DSIP product exists, and there is no approved dose, route, indication, contraindication profile, drug-interaction framework, or long-term safety label^{[2 –7 ]}.

Regulatory status

DSIP, also called emideltide, is not FDA-approved for any indication in the United States. No FDA-approved DSIP drug product was identified in FDA materials reviewed for this draft^{[2 –7 ]}.

April 2026 503A removal — procedural, not authorization

Under section 503A, state-licensed pharmacies and physicians may compound using a bulk drug substance only if the substance complies with an applicable USP/NF monograph, is a component of an FDA-approved drug product if no monograph exists, or appears on FDA’s 503A bulks list^{[3 ]}. FDA’s April 22, 2026 503A update states that “Emideltide (DSIP)” was removed from Category 2 because nominations were withdrawn and that FDA intends to consult PCAC on July 24, 2026 regarding possible inclusion of emideltide acetate and emideltide free base on the 503A bulks list^{[2 ,4 ]}.

Removal from Category 2 is not FDA approval and does not itself authorize routine compounding. DSIP is not listed in Category 1 in the April 22, 2026 document and was not identified on the 503A bulks list reviewed for this draft^{[2 –3 ]}.

503B and FDA safety-risk listing

For 503B outsourcing facilities, FDA states that a bulk substance may be used only if it appears on the 503B bulks list or the compounded drug appears on FDA’s shortage list at the relevant time^{[5 ]}. DSIP was not identified on the FDA 503B bulks list reviewed for this draft^{[6 ]}.

FDA’s safety-risk page lists Emideltide (DSIP) among withdrawn nominated substances and states that compounded drugs containing emideltide may pose immunogenicity risks for certain routes of administration and may have peptide-related impurity and API-characterization complexities. FDA also states that it has not identified safety-related information for the proposed route of administration and lacks sufficient information to know whether the drug would cause harm if administered to humans^{[7 ]}.

DSIP was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed for this draft^{[8 ]}. Date of last regulatory verification: May 5, 2026.

Research summary

Human DSIP research is concentrated in small studies from the 1980s. Schneider-Helmert and Schoenenberger tested acute intravenous synthetic DSIP in six middle-aged chronic insomniacs and reported longer sleep duration, better sleep quality, fewer interruptions, slightly more REM sleep, and no daytime sedation or other side effects in that small study^{[10 ]}. The abstract also noted a slight arousing effect during the first hour after injection^{[10 ]}.

Monti and colleagues later studied short-term DSIP administration in chronic insomniacs using polysomnographic recordings and a double-blind crossover design^{[11 ]}. DSIP was associated with decreases in nocturnal awakenings, NREM sleep latency, total waking time, and waking time after sleep onset, but the abstract states that no significant differences were found compared with baseline or placebo nights^{[11 ]}.

Where the evidence ends

These two studies illustrate the evidence boundary. DSIP was biologically and clinically interesting in early sleep research, but the human trials were very small, used intravenous administration, and predate current clinical trial standards, modern insomnia endpoints, and modern sleep-medicine practice^{[10 –11 ]}. The evidence does not support strong claims that DSIP treats insomnia, improves deep sleep, treats sleep apnea, improves recovery, or safely replaces approved insomnia treatments.

Research claims for stress, pain, withdrawal, endocrine effects, and mood are even less ready for clinical translation. MeSH summarizes reported DSIP effects across multiple physiologic systems, but a database definition is not a clinical efficacy determination^{[9 ]}. No large, modern randomized controlled trial was identified for DSIP in insomnia, chronic pain, addiction withdrawal, anxiety, athletic recovery, or anti-aging as of 2026-05-05.

Overall, DSIP should be described as an investigational sleep-related neuropeptide with historical human studies and insufficient contemporary evidence. The strongest claim supported by the cited literature is that DSIP has been studied for sleep architecture and chronic insomnia, not that it is proven to treat sleep disorders.

Public discourse

The FDA Pharmacy Compounding Advisory Committee scheduled DSIP-related substances for review and identified opioid withdrawal, chronic insomnia, and narcolepsy as the evaluated uses^{[4 ]}.

The FDA human drug compounding safety-risk page summarized safety concerns for withdrawn emideltide nominations^{[7 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

DSIP has no FDA-approved prescribing information. There is no FDA-reviewed label establishing contraindications, common adverse reactions, drug interactions, pregnancy or lactation safety, carcinogenicity data, or monitoring recommendations^{[2 –7 ]}.

The small 1981 sleep study reported no daytime sedation or other side effects in six chronic insomniacs, but that sample size is far too small to establish safety^{[10 ]}. The 1987 crossover study did not establish a modern adverse-event profile^{[11 ]}.

Compounding-related risks

FDA’s compounding safety concerns include potential immunogenicity, peptide-related impurity concerns, and API-characterization complexity^{[7 ]}. These issues are especially relevant for injectable products and for products sold online as research peptides.

Theoretical risks

Theoretical concerns include sedation, paradoxical arousal, neuroendocrine effects, interactions with hypnotics or psychiatric medications, and impairment in activities requiring alertness. These concerns are plausible based on the target domain but not quantified in modern clinical studies.

Long-term safety data are insufficient. There is no large postmarketing database, no FDA label, and no contemporary randomized trial program adequate to characterize rare or delayed harms.

Available through

DSIP is not currently available through routine FDA-compliant prescription or compounding channels in the United States as of 2026-05-05^{[2 –7 ]}. It is not FDA-approved, is not on the 503A or 503B bulks lists, and awaits PCAC review scheduled for July 24, 2026^{[2 ,4 ]}.

ProPeptideGuide does not link to or endorse grey-market vendors, research-chemical sellers, online peptide shops, or clinics advertising DSIP for sleep, stress, withdrawal, recovery, or anti-aging use.